• Study on Mitomycin, Capecitabine, Ipilimumab, and Nivolumab for Muscle Invasive Bladder Cancer Treatment in Patients Seeking Bladder-Sparing Options

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    The Netherlands
  • Study of Nivolumab with Chemotherapy for Children and Teenagers with Refractory or Relapsing Solid Tumors or Lymphoma

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    France
  • Study on PRAX-628 for Adults with Focal Epilepsy Taking 1 to 3 Anti-Seizure Medications

    Not recruiting

    4 1
    Investigated Diseases:
    Investigated Drugs:
    Italy Poland Spain
  • Study of MCLA-129 with Chemotherapy and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Belgium France Germany Italy The Netherlands Spain
  • Study on the Effects of AZD5004 for Adults with Obesity or Overweight and a Related Medical Condition

    Not recruiting

    2 1
    Investigated Diseases:
    Investigated Drugs:
    Germany
  • Study on Lutetium (177Lu) Zadavotide Guraxetan for Patients with Recurrent Grade 3 and Grade 4 Glioma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    Norway
  • Study of cabozantinib with atezolizumab compared to sorafenib in untreated patients with advanced liver cancer (hepatocellular carcinoma)

    Not recruiting

    3 1 1 1
    Belgium France Hungary Romania Spain
  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Belgium France Germany
  • Study of Dasatinib and Quercetin combination for treating liver fibrosis in patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

    Not recruiting

    2 1 1
    The Netherlands
  • Study on Norucholic Acid for Treating Primary Sclerosing Cholangitis in Patients

    Not recruiting

    3 1
    Investigated Diseases:
    Investigated Drugs:
    Austria Denmark Finland France Germany Hungary +3

powered by